Luciano Puzer

List of Publications by Year
in descending order

29 papers	670 citations	623734 14 h-index	552781 26 g-index
29 all docs	29 docs citations	29 times ranked	960 citing authors

#	Article	IF	Citations
1	Human Tissue Kallikreins-Related Peptidases Are Targets for the Treatment of Skin Desquamation Diseases. Frontiers in Medicine, 2021, 8, 777619.	2.6	7
2	Generation of recombinant antibodies against human tissue kallikrein 7 to treat skin diseases. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127626.	2.2	4
3	Functional and structural characterization of an ecotin-like serine protease inhibitor from Trypanosoma cruzi. International Journal of Biological Macromolecules, 2020, 151, 459-466.	7.5	5
4	3-Acyltetramic acids as a novel class of inhibitors for human kallikreins 5 and 7. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1094-1098.	2.2	36
5	The tick-derived rBmTI-A protease inhibitor attenuates the histological and functional changes induced by cigarette smoke exposure. Histology and Histopathology, 2018, 33, 289-298.	0.7	12
6	Functional and Evolutionary Characterization of a UDP-Xylose Synthase Gene from the Plant Pathogen Xylella fastidiosa, Involved in the Synthesis of Bacterial Lipopolysaccharide. Biochemistry, 2017, 56, 779-792.	2.5	0
7	Discovery of a new isomannide-based peptidomimetic synthetized by Ugi multicomponent reaction as human tissue kallikrein 1 inhibitor. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 314-318.	2.2	6
8	Vioserpin, a serine protease inhibitor from Gloeobacter violaceus possibly regulated by heparin. Biochimie, 2016, 127, 115-120.	2.6	5
9	The natural flavone fukugetin as a mixed-type inhibitor for human tissue kallikreins. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1485-1489.	2.2	12
10	Synthesis, biological evaluation and molecular modeling of pseudo-peptides based statine as inhibitors for human tissue kallikrein 5. European Journal of Medicinal Chemistry, 2016, 112, 39-47.	5.5	10
11	Isomannide-Based Peptidomimetics as Inhibitors for Human Tissue Kallikreins 5 and 7. ACS Medicinal Chemistry Letters, 2014, 5, 128-132.	2.8	31
12	Human tissue kallikreins 3 and 5 can act as plasminogen activator releasing active plasmin. Biochemical and Biophysical Research Communications, 2013, 433, 333-337.	2.1	14
13	Isomannide derivatives as new class of inhibitors for human kallikrein 7. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 6072-6075.	2.2	22
14	Biological evaluation and docking studies of natural isocoumarins as inhibitors for human kallikrein 5 and 7. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6112-6115.	2.2	45
15	Leviserpin: A Serine Peptidase Inhibitor (Serpin) from the Sugarcane Weevil Sphenophorus levis. Protein Journal, 2011, 30, 404-412.	1.6	6
16	Plasminogen hydrolysis by cathepsin S and identification of derived peptides as selective substrate for cathepsin V and cathepsin L inhibitor. Biological Chemistry, 2010, 391, 561-570.	2.5	7
17	Cathepsin V, but not cathepsins L, B and K, may release angiostatin-like fragments from plasminogen. Biological Chemistry, 2008, 389, 195-200.	2.5	16
18	Recombinant expression and characterization of aXylella fastidiosacysteine protease differentially expressed in a nonpathogenic strain. FEMS Microbiology Letters, 2006, 261, 187-193.	1.8	11

#	Article	IF	Citations
19	Recombinant human cathepsin X is a carboxymonopeptidase only: a comparison with cathepsins B and L. Biological Chemistry, 2005, 386, 1191-5.	2.5	30
20	A possible alternative mechanism of kinin generation in vivo by cathepsin L. Biological Chemistry, 2005, 386, 699-704.	2.5	17
21	Defining the substrate specificity of mouse cathepsin P. Archives of Biochemistry and Biophysics, 2005, 435, 190-196.	3.0	9
22	Plasma prekallikrein/kallikrein processing by lysosomal cysteine proteases. Biological Chemistry, 2004, 385, 1087-91.	2.5	9
23	Carboxydipeptidase activities of recombinant cysteine peptidases. FEBS Journal, 2004, 271, 1046-1053.	0.2	25
24	Kininogenase activity of Thalassophryne nattereri fish venom. Biochemical Pharmacology, 2004, 68, 2151-2157.	4.4	55
25	Positional-scanning combinatorial libraries of fluorescence resonance energy transfer peptides to define substrate specificity of carboxydipeptidases: assays with human cathepsin B. Analytical Biochemistry, 2004, 335, 244-252.	2.4	89
26	Production of L-DOPA under heterogeneous asymmetric catalysis. Catalysis Communications, 2004, 5, 631-634.	3.3	28
27	Comparative substrate specificity analysis of recombinant human cathepsin V and cathepsin L. Archives of Biochemistry and Biophysics, 2004, 430, 274-283.	3.0	60
28	S3 to S3' subsite specificity of recombinant human cathepsin K and development of selective internally quenched fluorescent substrates. Biochemical Journal, 2003, 373, 981-986.	3.7	60
29	Cathepsin B carboxydipeptidase specificity analysis using internally quenched fluorescent peptides. Biochemical Journal, 2002, 368, 365-369.	3.7	39